Oncotelic Therapeutics, Inc.
OTLC · OTCMCIK 908259fmd_1MQY0CFXJRM1BT887PYTDBXZ12Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2026, 66 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Operating income
- (3)
- Net income
- 249
Latest quarter · Q2 FY2026
Millions- Total revenues
- 0
- Operating income
- (1)
- Net income
- 0
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- -65.7%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Oncotelic Therapeutics, Inc. (OTLC) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$3.2 million | -$3.6 million | 10-K 2026-04-15 · proof | |
| Net income | $249.3 million | -$4.5 million | 10-K 2026-04-15 · proof | |
| Cash from operating activities | -$1.4 million | -$740,277 | 10-K 2026-04-15 · proof | |
| Total assets | $393.1 million | $26.7 million | +1,373.5% | 10-K 2026-04-15 · proof |
| Total liabilities | $131.4 million | $19.2 million | +584.2% | 10-K 2026-04-15 · proof |
| Cash and cash equivalents | $88,857 | $86,128 | +3.2% | 10-K 2026-04-15 · proof |
- What was Oncotelic Therapeutics, Inc. (OTLC)'s operating income in fiscal 2025?
- Oncotelic Therapeutics, Inc. (OTLC) reported operating income of -$3.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$3.6 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What was Oncotelic Therapeutics, Inc. (OTLC)'s net income in fiscal 2025?
- Oncotelic Therapeutics, Inc. (OTLC) reported net income of $249.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$4.5 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What was Oncotelic Therapeutics, Inc. (OTLC)'s cash from operating activities in fiscal 2025?
- Oncotelic Therapeutics, Inc. (OTLC) reported cash from operating activities of -$1.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$740,277 the year before. Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What are Oncotelic Therapeutics, Inc. (OTLC)'s total assets?
- As of Dec 31, 2025, Oncotelic Therapeutics, Inc. (OTLC) reported total assets of $393.1 million, against $26.7 million a year earlier (+1,373.5%). Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What are Oncotelic Therapeutics, Inc. (OTLC)'s total liabilities?
- As of Dec 31, 2025, Oncotelic Therapeutics, Inc. (OTLC) reported total liabilities of $131.4 million, against $19.2 million a year earlier (+584.2%). Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What are Oncotelic Therapeutics, Inc. (OTLC)'s cash and cash equivalents?
- As of Dec 31, 2025, Oncotelic Therapeutics, Inc. (OTLC) reported cash and cash equivalents of $88,857, against $86,128 a year earlier (+3.2%). Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:OTLC&period_type=annual&limit=5"Information only, not investment advice.